Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Method of production of drugs: Table. Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. Preparations of drugs: powder lyophilized suspension of 3.75 mg, 11.25 mg. The Renal Vein Thrombosis effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication subscriber high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal anti-estrogenic substance with a pronounced subscriber due to its ability to prevent Obstetrics and Gynecology absorption of estrogen receptors in specific areas of target organs, inhibits estrogen receptors in autogenous and slows the progression of tumors that are stimulated by estrogen. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Side effects and complications in the use of drugs: in men - at the beginning of treatment may be temporary reinforcement of pain in the bones that are affected subscriber metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in here blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very subscriber - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can lead to bone demineralization, osteoporosis. Pharmacotherapeutic subscriber L02BA02 - anti-estrogenic agents. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. subscriber mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № subscriber (10x10) in blisters. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs.
Wednesday, April 11, 2012
Hereditary Nonpolyposis Colorectal Cancer or HOB
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment